On this point, siRNA therapeutics coupled to cancer-targeting nanoparticles represent an ideal avenue for targeting MYH in PC cells, while overcoming the current lack of pharmacological inhibitors against MYH [36–38]. The gene discussed is MUTYH; the disease is pachyonychia congenita.